← Back to GLP-1 DatabaseActive Ingredient liraglutide Drug Class GLP-1 Receptor Agonist Dosage & Administration Injectable Approved Indications Weight Loss FDA Approved December 23, 2014
Saxenda
liraglutide
GLP-1 Receptor AgonistInjectableWeight Loss
Manufacturer: Novo NordiskFDA Approved: December 23, 2014Starting from $950.00/mo
Overview
Saxenda is a daily injectable GLP-1 receptor agonist approved for chronic weight management, an earlier-generation alternative to semaglutide.
Clinical Data
Weight Loss Efficacy
~5-8% body weight loss in clinical trials
Common Side Effects
nauseahypoglycemiadiarrheaconstipationheadache
Community Side-Effect Reports
User-reported data — not medical advice. Consult your healthcare provider.
Provider Pricing
Mochi Health
$950.00/mo
+ consultation fee: $50.00
PlushCare
$980.00/mo
+ consultation fee: $129.00